Prognosis of patients treated in a single neurosurgical reference centre for brain metastasis caused by dormant disseminated cells
- Lorenzo Ferlini
- Lorenzo Peluso
- Valentina Lolli
- Nicolas Gaspard
- Florence Lefranc
Affiliations: Department of Neurology, Erasmus Hospital, Free University of Bruxelles, B‑1070 Brussels, Belgium, Department of Intensive Care, Erasmus Hospital, Free University of Bruxelles, B‑1070 Brussels, Belgium, Department of Radiology, Erasmus Hospital, Free University of Bruxelles, B‑1070 Brussels, Belgium, Department of Neurosurgery, Erasmus Hospital, Free University of Bruxelles, B‑1070 Brussels, Belgium
- Published online on: April 8, 2021 https://doi.org/10.3892/ol.2021.12715
Copyright: © Ferlini
et al. This is an open access article distributed under the
terms of Creative
Commons Attribution License.
Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
This article is mentioned in:
Brain metastasis (BM) is a frequent complication of systemic cancer usually associated with poor prognosis. Survival depends on numerous factors, which complicates prognosis and treatment. It has been suggested that BM growing from previously dormant disseminated tumour cells (DTCs) may exhibit a milder phenotype than BM derived from continuously progressing metastatic cells; however, to the best of our knowledge, the prognosis of patients presenting with BM from dormant DTCs is unknown. The present study retrospectively compared survival data, collected from a single neurosurgical centre, between patients presenting with BM from previously dormant DTCs and patients with non‑dormant BM. A total of 262 medical records were reviewed. In the univariate Cox regression analysis, the median survival of the dormant BM group was statistically longer than that of the non‑dormant group (P=0.048); a trend towards a longer survival persisted after correcting for age, presence of breast cancer and treatment options (P=0.057), which are all factors known to influence outcome. The improved outcome of these patients could be considered in models for prognostication. Moreover, the development of therapies able to eradicate dormant DTCs could provide a new promising strategy to prolong the survival of patients with a favourable prognosis.